ARTES steps further into the vaccine business by acquiring Anavax

ARTES Biotech­nol­o­gy announces today the acquire­ment of the ANAVAX virus-like par­ti­cle (VLP) tech­nol­o­gy from Select Vac­cines Ltd. ANAVAX is a patent-pro­tect­ed VLP tech­nol­o­gy that can be applied to the pre­ven­tion of sev­er­al infec­tious dis­eases.

With the com­bi­na­tion of two excel­lent tech­nol­o­gy plat­forms, ANAVAX and the Hansenu­la expres­sion sys­tem, ARTES has posi­tioned itself as a unique part­ner for the vac­cine indus­try.

The ANAVAX VLP plat­form has already been applied to the devel­op­ment of adju­vant-free vac­cines against avian and swine flu, malar­ia and HIV. Hansenu­la is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and is rec­om­mend­ed by the WHO for hepati­tis B vac­ci­na­tion cam­paigns. Togeth­er, the plat­forms build a new approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines. ARTES’ busi­ness plan is to enhance its posi­tion as a pre­ferred devel­op­ment part­ner for vac­cine man­u­fac­tur­er.